Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 300

Similar articles for PubMed (Select 22981547)

1.

Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.

Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB.

J Am Coll Cardiol. 2012 Oct 2;60(14):1271-7. doi: 10.1016/j.jacc.2012.07.029. Epub 2012 Sep 12.

2.

Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.

Dorenkamp M, Bonaventura K, Leber AW, Boldt J, Sohns C, Boldt LH, Haverkamp W, Frei U, Roser M.

Eur Heart J. 2013 Feb;34(6):451-61. doi: 10.1093/eurheartj/ehs355. Epub 2012 Oct 22.

3.

Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.

Gladwell D, Henry T, Cook M, Akehurst R.

Appl Health Econ Health Policy. 2014 Dec;12(6):611-22. doi: 10.1007/s40258-014-0116-7.

PMID:
25086585
4.

Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator.

Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA.

J Clin Hypertens (Greenwich). 2009 Oct;11(10):555-63. doi: 10.1111/j.1751-7176.2009.00163.x.

5.

Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands.

Henry TL, De Brouwer BF, Van Keep MM, Blankestijn PJ, Bots ML, Koffijberg H.

J Med Econ. 2015 Jan;18(1):76-87. doi: 10.3111/13696998.2014.978453. Epub 2014 Nov 7.

PMID:
25367314
6.

Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.

Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA; Symplicity HTN-2 Investigators.

Circulation. 2012 Dec 18;126(25):2976-82. doi: 10.1161/CIRCULATIONAHA.112.130880.

7.

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.

Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR.

Clin Ther. 2012 Jul;34(7):1531-43. doi: 10.1016/j.clinthera.2012.06.006. Epub 2012 Jun 27.

PMID:
22742885
8.

A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.

Anis AH, Sun H, Singh S, Woolcott J, Nosyk B, Brisson M.

Pharmacoeconomics. 2006;24(4):387-400.

PMID:
16605284
9.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

10.

Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.

Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, Cass A.

Value Health. 2010 Mar-Apr;13(2):196-208. doi: 10.1111/j.1524-4733.2009.00668.x. Epub 2009 Oct 29.

PMID:
19878493
11.

A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.

Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL.

Ann Emerg Med. 2013 Jan;61(1):46-55. doi: 10.1016/j.annemergmed.2012.04.020. Epub 2012 May 24.

12.
13.

Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.

Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.

Can J Clin Pharmacol. 2009 Summer;16(2):e331-45. Epub 2009 Jun 16.

14.
15.

Cost-effectiveness of captopril therapy after myocardial infarction.

Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, Kuntz KM, Lee TH.

J Am Coll Cardiol. 1995 Oct;26(4):914-9.

17.

Renal denervation in moderate treatment-resistant hypertension.

Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Böhm M, Schmieder RE.

J Am Coll Cardiol. 2013 Nov 12;62(20):1880-6. doi: 10.1016/j.jacc.2013.06.023. Epub 2013 Jul 10.

18.

Cost-effectiveness of impedance cardiography testing in uncontrolled hypertension.

Ferrario CM, Smith RD; CONTROL Trial Investigators.

Am Heart Hosp J. 2006 Fall;4(4):279-89.

PMID:
17086009
19.

Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings.

Borisenko O, Beige J, Lovett EG, Hoppe UC, Bjessmo S.

J Hypertens. 2014 Mar;32(3):681-92. doi: 10.1097/HJH.0000000000000071.

PMID:
24378998
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk